Collects tissue and samples from people with mesothelioma and mesothelin-linked cancers
Studies patients with mesothelioma and other mesothelin-expressing cancers, collecting samples and follow-up data.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 9 Sept 2013
- Expected to end
- 25 Jul 2033
- Type of study
- Observational
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with malignant mesothelioma or other cancers that make mesothelin, a protein on tumor cells. They give blood, urine, tumor and fluid samples and are followed over time.
- Age
- 2 Years to 100 Years. People with mesothelioma can join from age 2. People with the other cancers must be 18 or older.
- Sex
- All sexes can join.
- Disease stage
- Malignant mesothelioma, or thymic carcinoma, pancreatic or biliary adenocarcinoma, or lung, gastric or ovarian cancer, or another solid tumor known to express mesothelin. The diagnosis must be confirmed by tissue testing.
- Biomarker or test result
- For cancers other than mesothelioma, the solid tumor must be known to express mesothelin.
Main reasons for not taking part
- Active serious organ disease that makes a biopsy riskier, such as heart disease, recent heart attack, heart failure or lung problems
- Pregnant women
- Other active medical or mental illness that may raise the risk, as judged by the lead doctor
- Adults unable to give informed consent
The registry criteria, word for word
Show all 8 criteriaShow less
Who cannot take part
- Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator
- Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction
- Pregnant women
Other criteria
- INCLUSION CRITERIA:
- All participants >= 2 years of age with malignant mesothelioma
- All participants >=18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin
- Confirmed pathological diagnosis is required
- Ability and willingness of participant to provide informed consent to participation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 100 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Cathy I Wagner, R.N.Taking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States. * The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis. * Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease. * In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.
Objectives:
-To allow sample acquisition for use in the study of mesothelioma.
Eligibility:
* All participants age greater than or equal to 2 years with malignant mesothelioma OR * All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin * Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18
Design:
* Up to 1000 subjects will be enrolled. * Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma. * Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking. * Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.
The group in the trial
- 1/Eligible cancer diagnosis
Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
- Plain-language title
- Collects tissue and samples from people with mesothelioma and mesothelin-linked cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT01950572, who can take part
- Publications
- Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020
- Record updated
- 12 November 2026